Dr. Reddy’s launches Valganciclovir Tablets

16 Dec 2014 Evaluate

Dr. Reddy’s Laboratories has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of Valcyte (Valganciclovir) tablets in the US market on December 15, 2014, approved by the United States Food & Drug Administration (USFDA). The company’s Valganciclovir tablets, USP in 450 mg is available in bottle counts of 60.

The Valcyte (Valganciclovir) tablets brand had U.S. sales of around $440 million MAT for the most recent twelve months ending in October 2014, according to IMS Health.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1275.05 -1.95 (-0.15%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×